Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Accounts Payables: 2009-2024

Historic Accounts Payables for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to $45.7 million.

  • Ani Pharmaceuticals' Accounts Payables rose 14.62% to $69.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.8 million, marking a year-over-year increase of 14.62%. This contributed to the annual value of $45.7 million for FY2024, which is 24.46% up from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Accounts Payables of $45.7 million as of FY2024, which was up 24.46% from $36.7 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' Accounts Payables registered a high of $45.7 million during FY2024, and its lowest value of $11.3 million during FY2020.
  • Its 3-year average for Accounts Payables is $37.2 million, with a median of $36.7 million in 2023.
  • In the last 5 years, Ani Pharmaceuticals' Accounts Payables dropped by 22.90% in 2020 and then skyrocketed by 103.95% in 2021.
  • Ani Pharmaceuticals' Accounts Payables (Yearly) stood at $11.3 million in 2020, then soared by 103.95% to $23.0 million in 2021, then grew by 27.60% to $29.3 million in 2022, then increased by 25.18% to $36.7 million in 2023, then increased by 24.46% to $45.7 million in 2024.